ABVC
ABVC BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.96
−3.99%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
Market Cap
$25.59M
MomentumView details →
1D Return
−3.99%
YTD Return
−57.28%
RSI (14)
47.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
Market Cap
$25.59M
RSI (14)
47.6
MomentumView details →
1D Return
−3.99%
YTD Return
−57.28%
SummaryUpdated Jun 1, 2026
ABVC BioPharma, Inc. (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in Fremont, California. The company operates as a subsidiary of YuanGene Corporation and focuses on developing innovative drugs and medical devices to address unmet medical needs. ABVC has built a diverse pipeline of therapeutic candidates targeting various conditions including cancer, mental health disorders, and retinal diseases, with multiple compounds currently progressing through different phases of clinical trials.
Similar companies
Latest newsMore news →